Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMS American Shared Hospital Services	$2.40	$2.55	$2.30 ▼ $4.60	$15.48M	0.3	44,406 shs	82,485 shs
BIAF bioAffinity Technologies	$0.36 +46.9%	$0.31	$0.16 ▼ $2.99	$6.97M	2.54	4.06 million shs	191.22 million shs
KZIA Novogen	$6.53 -0.9%	$4.90	$2.86 ▼ $79.00	$6.64M	2.48	384,137 shs	13,710 shs
NRSN NeuroSense Therapeutics	$1.98 -10.0%	$1.56	$0.51 ▼ $2.60	$30.07M	1.62	280,327 shs	610,254 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMS American Shared Hospital Services	0.00%	-2.44%	+0.84%	-14.59%	-10.45%
BIAF bioAffinity Technologies	+46.90%	+43.33%	+32.12%	+37.42%	-81.06%
KZIA Novogen	-0.91%	-26.71%	+74.60%	+48.39%	-37.42%
NRSN NeuroSense Therapeutics	-10.00%	-19.18%	+30.26%	+98.99%	+132.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMS American Shared Hospital Services	2.1699 of 5 stars	0.0	5.0	1.6	1.7	1.9
BIAF bioAffinity Technologies	1.5818 of 5 stars	3.0	2.0	3.3	0.8	0.0
KZIA Novogen	3.8483 of 5 stars	3.5	5.0	3.3	0.0	0.0
NRSN NeuroSense Therapeutics	2.5481 of 5 stars	3.5	3.0	3.3	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMS American Shared Hospital Services	0.00	N/A	N/A	N/A
BIAF bioAffinity Technologies	2.00	Hold	$6.00	1,567.13% Upside
KZIA Novogen	3.00	Buy	$57.50	780.55% Upside
NRSN NeuroSense Therapeutics	3.00	Buy	$14.00	607.07% Upside

Current Analyst Ratings Breakdown

Latest AMS, NRSN, KZIA, and BIAF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	KZIA Novogen	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
5/12/2025	NRSN NeuroSense Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	NRSN NeuroSense Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
4/1/2025	BIAF bioAffinity Technologies	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMS American Shared Hospital Services	$28.34M	0.55	$0.89 per share	2.70	$4.68 per share	0.51
BIAF bioAffinity Technologies	$9.36M	1.09	N/A	N/A	$0.17 per share	2.12
KZIA Novogen	$1.51M	4.37	N/A	N/A	($9.87) per share	-0.66
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	$0.19 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMS American Shared Hospital Services	$2.19M	$0.60	10.91	8.00	N/A	5.00%	-4.20%	-2.09%	8/13/2025 (Estimated)
BIAF bioAffinity Technologies	-$9.04M	-$0.72	N/A	∞	N/A	-110.53%	-367.64%	-154.15%	8/13/2025 (Estimated)
KZIA Novogen	-$17.56M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	-$10.21M	-$0.54	N/A	∞	N/A	N/A	N/A	-445.40%	N/A

Latest AMS, NRSN, KZIA, and BIAF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	BIAF bioAffinity Technologies	-$0.16	-$0.16	N/A	-$0.16	$2.11 million	$1.85 million
4/7/2025	Q4 2024	NRSN NeuroSense Therapeutics	-$0.12	-$0.06	+$0.06	-$0.06	N/A	N/A
3/31/2025	Q4 2024	BIAF bioAffinity Technologies	-$0.14	-$0.21	-$0.07	-$0.21	$2.42 million	$2.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMS American Shared Hospital Services	N/A	N/A	N/A	N/A	N/A
BIAF bioAffinity Technologies	N/A	N/A	N/A	N/A	N/A
KZIA Novogen	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMS American Shared Hospital Services	0.58	1.87	1.87
BIAF bioAffinity Technologies	0.27	0.55	0.53
KZIA Novogen	N/A	0.21	N/A
NRSN NeuroSense Therapeutics	N/A	2.21	2.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMS American Shared Hospital Services	23.16%
BIAF bioAffinity Technologies	1.64%
KZIA Novogen	30.89%
NRSN NeuroSense Therapeutics	1.04%

Insider Ownership

Company	Insider Ownership
AMS American Shared Hospital Services	23.80%
BIAF bioAffinity Technologies	16.93%
KZIA Novogen	1.00%
NRSN NeuroSense Therapeutics	27.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMS American Shared Hospital Services	10	6.45 million	4.92 million	Not Optionable
BIAF bioAffinity Technologies	10	28.46 million	23.64 million	Not Optionable
KZIA Novogen	12	1.01 million	997,000	Optionable
NRSN NeuroSense Therapeutics	10	13.67 million	9.92 million	Not Optionable

AMS, NRSN, KZIA, and BIAF Headlines

Recent News About These Companies

NeuroSense Completes Key Meeting with Health Canada for ALS Drug Approval

June 26 at 10:11 AM | tipranks.com

NeuroSense Therapeutics (NRSN) Expected to Announce Earnings on Tuesday

June 17, 2025 | americanbankingnews.com

Top Nasdaq Companies by Market Cap Ranked by Kalkine

June 7, 2025 | kalkinemedia.comK

Neurosense, awaiting Canada approval, scales PrimeC production

May 15, 2025 | alsnewstoday.comA

D. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy Recommendation

May 14, 2025 | msn.com

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

May 12, 2025 | benzinga.com

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

May 7, 2025 | prnewswire.com

NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership

April 24, 2025 | tipranks.com

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

April 24, 2025 | prnewswire.com

NeuroSense Therapeutics Presents Promising Phase 2b Data on PrimeC for ALS at AAN Meeting

April 10, 2025 | sohu.comS

NeuroSense Therapeutics Reports Year-End 2024 Financial Results and Provides Business Updates

April 10, 2025 | sohu.comS

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

April 9, 2025 | prnewswire.com

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

April 7, 2025 | prnewswire.com

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

April 4, 2025 | prnewswire.com

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

March 20, 2025 | businesswire.com

NeuroSense Advances PrimeC Commercialization in Canada

March 19, 2025 | tipranks.com

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

March 17, 2025 | businesswire.com

Life Saving Innovation in Neurodegenerative Disease Treatment: An Interview with Alon Ben-Noon, CEO & Founder of NeuroSense Therapeutics

March 12, 2025 | techbullion.comT

NeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS Treatment

February 19, 2025 | tipranks.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Elevance Health (ELV) and Genmab (GMAB)

February 4, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Ignore the Noise—Samsara Stock Is Still a Strong Buy
By Sam Quirke | June 12, 2025
View Ignore the Noise—Samsara Stock Is Still a Strong Buy

AMS, NRSN, KZIA, and BIAF Company Descriptions

American Shared Hospital Services NYSEAMERICAN:AMS

$2.40 0.00 (0.00%)

As of 06/26/2025 04:10 PM Eastern

American Shared Hospital Services provides stereotactic radiosurgery and advanced radiation therapy equipment. It operates in two segments, Medical Equipment Leasing, and Retail. The company offers radiosurgery equipment for the Gamma Knife stereotactic radiosurgery, a non-invasive procedure to treat malignant and benign brain tumors, and arteriovenous malformations, as well as for trigeminal neuralgia. It also provides financing services for Leksell Gamma Knife units; and leases medical equipment. In addition, the company offers proton beam radiation therapy services in Orlando, Florida and Long Beach, California, as well as offers planning, installation, reimbursement, and marketing support services to its customers. The company markets its solutions to cancer treatment centers, hospitals, and cancer networks worldwide. American Shared Hospital Services was founded in 1980 and is based in San Francisco, California.

bioAffinity Technologies NASDAQ:BIAF

$0.36 +0.11 (+46.90%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$0.34 -0.02 (-5.25%)

As of 06/26/2025 08:00 PM Eastern

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

Novogen NASDAQ:KZIA

$6.53 -0.06 (-0.91%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$6.53 0.00 (0.00%)

As of 06/26/2025 07:35 PM Eastern

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

NeuroSense Therapeutics NASDAQ:NRSN

$1.98 -0.22 (-10.00%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$2.00 +0.02 (+1.06%)

As of 06/26/2025 08:00 PM Eastern

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time